Management of Severe Bleeding in Patients Treated with Direct Oral Anticoagulants: An Observational Registry Analysis

Anesthesiology

Volumn 127, Issue 1, 2017, Pages 111-120

  Albaladejo, Pierre ^a,n   Samama, Charles Marc ^b,h   Sié, Pierre ^c   Kauffmann, Sophie ^d   Mémier, Vincent ^c,i   Suchon, Pierre ^e,m   Viallon, Alain ^f   David, Jean Stéphane ^g   Gruel, Yves ^h,j   Bellamy, Lorenn ^i,o   De Maistre, Emmanuel ^j,p   Romegoux, Pauline ^k,q   Thoret, Sophie ^l,r   Pernod, Gilles ^a,n,s   Bosson, Jean Luc ^j,k   Bazin, Jean Etienne ^d   Combaret, Nicolas ^d   Cherprenet, Anne Laure ^d   Fares, Moustafa ^d   Dufraisse, Sophie ^d   Minville, Vincent ^c   Morange, Pierre ^m   Leone, Marc ^m   Cohen, William ^m   Neánt, Nadège ^m   Marlu, Raphaël ⁿ   Carpentier, Françoise ⁿ   Defaye, Pascal ⁿ   Mismetti, Patrick ^f   Molliex, Serge ^a,g   Lanoiseleé, Julien ^f   Piriou, Vincent ^g   Delaleu Rague, Carine ^u   Lefèvre, Mathilde ^b   Lagrange, Sophie ^v   Ardillon, Laurent ^w   Ozier, Yves ^x   Bovet, Julien ^y   Steib, Annick ^z   Mebaouj, Sonia ^aa   Profumo, Louis ^ab   Roullet, Stéphanie ^ac   Smadja, David ^ad   Meyer, Guy ^ae   Journois, Didier ^af   Trinh Duc, Albert ^ag   Viard, Thibault ^ah   Belle, Loic ^ai   Levrat, Albrice ^aj   Gautheron, Etienne ^ak   Heluwaert, Frédéric ^al   Schlumberger, Sylvie ^am   Blanié, Antonia ^aj   Benhamou, Dan ^ai   Flaujac, Claire ^ah   Rosencher, Nadia ^ae   Beloeil, Hélène ^af   Blery, Catherine ^b   Daviet, Lauren ^x   Gueret, Pierre ^w   Faraoni, David ^v   Schved, Jean François ^u   Deras, Pauline ^t   Jaber, Samir ^r   Gueugniaud, Pierre Yves ^q   Floccard, Bernard ^p   Asehnoune, Karim ^o   Paulus, Jérôme ^j   Amrani, Omar ⁱ   Gonthier, Marie Caroline ^h   Huisse, Marie Geneviève ^g   Josserand, Julien ^f   De Raucourt, Emmanuelle ^m   Defournel, Cécile ^c   Dubois, Yohann ^d   Bouvier, Stéphane ^a   Roy, Pierre Marie ^l   Lasocki, Sigismond ^k   Carmagnac, Christian ^h   Chastagner, Catherine ^g   Thouret, Jean Marc ^f   Sevestre, Marie Antoinette ^q   Meaudre, Eric ^x   Cungi, Pierre Julien ^y   Susen, Sophie ^aa   Lefrant, Jean Yves ^ab   MacEy, Stéphane ^p   Rieu, Jean Baptiste ^y   Godier, Anne ^x   more..

^a UNIV GRENOBLE ALPES   (France)

^b Institut Cochin   (France)

^c TOULOUSE UNIVERSITY HOSPITAL   (France)

^d UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^e AIX MARSEILLE UNIVERSITY   (France)

^f UNIVERSITÉ JEAN MONNET   (France)

^g CENTRE HOSPITALIER LYON SUD   (France)

^h UNIVERSITÉ DE TOURS   (France)

ⁱ BREST UNIVERSITY HOSPITAL   (France)

^j DIJON UNIVERSITY HOSPITAL   (France)

^k Center of Clinical Investigation   (France)

^l Biostatistic Unit   (France)

^m Service des Maladies Infectieuses   (France)

ⁿ GRENOBLE UNIVERSITY HOSPITAL   (France)

^o UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^p BORDEAUX UNIVERSITY HOSPITAL   (France)

^q HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^r Agen Hospital   (France)

^s Hospital of Annecy   (France)

^t FOCH HOSPITAL   (France)

^u BICÊTRE HOSPITAL   (France)

^v RENNES UNIVERSITY HOSPITAL   (France)

^w BRUGMANN UNIVERSITY HOSPITAL   (Belgium)

^x MONTPELLIER UNIVERSITY HOSPITAL   (France)

^y EDOUARD HERRIOT HOSPITAL   (France)

^z NANTES UNIVERSITY HOSPITAL   (France)

^aa BICHAT HOSPITAL   (France)

^ab BEAUJON HOSPITAL   (France)

^ac Alpes Léman Hospital   (France)

^ad Groupe Hospitalier Mutualiste   (France)

^ae ANGERS UNIVERSITY HOSPITAL   (France)

^af Chambery Hospital   (France)

^ag AMIENS UNIVERSITY HOSPITAL   (France)

^ah Sainte Anne's Military Hospital   (France)

^ai LILLE UNIVERSITY HOSPITAL   (France)

^aj NÎMES UNIVERSITY HOSPITAL   (France)

^ak Gap   (France)

^al Geriatrics Department   (France)

^am Rotschild Foundation   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; APIXABAN; DABIGATRAN; PROTHROMBIN COMPLEX; RIVAROXABAN; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR; PROTHROMBIN COMPLEX CONCENTRATES; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE;

AGED; ANTICOAGULANT THERAPY; ARTICLE; BRAIN HEMORRHAGE; CLINICAL OUTCOME; COHORT ANALYSIS; CREATININE CLEARANCE; DISEASE SEVERITY; DRUG BLOOD LEVEL; FEMALE; GASTROINTESTINAL HEMORRHAGE; HOSPITAL MORTALITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; BLOOD; CLINICAL TRIAL; EUROPE; HEMORRHAGE; ORAL DRUG ADMINISTRATION; REGISTER; VERY ELDERLY;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; BLOOD COAGULATION FACTORS; COHORT STUDIES; DABIGATRAN; EUROPE; FEMALE; HEMORRHAGE; HUMANS; MALE; PROSPECTIVE STUDIES; PYRAZOLES; PYRIDONES; REGISTRIES; RIVAROXABAN;

EID: 85017422736     PISSN: 00033022     EISSN: 15281175     Source Type: Journal    
DOI: 10.1097/ALN.0000000000001631     Document Type: Article

References (35)

1. van der Hulle T, Kooiman J, den Exter PL, Dekkers OM, Klok FA, Huisman MV: Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: A systematic review and meta-analysis. J Thromb Haemost 2014; 12:320-8
2. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A, Yamashita T, Antman EM: Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: A meta-analysis of randomised trials. Lancet 2014; 383:955-62
3. Larsen TB, Skjøth F, Nielsen PB, Kjældgaard JN, Lip GY: Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: Propensity weighted nationwide cohort study. BMJ 2016; 353:i3189
4. Piccini JP, Garg J, Patel MR, Lokhnygina Y, Goodman SG, Becker RC, Berkowitz SD, Breithardt G, Hacke W, Halperin JL, Hankey GJ, Nessel CC, Mahaffey KW, Singer DE, Califf RM, Fox KA; ROCKET AF Investigators: Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: Results from the ROCKET AF trial. Eur Heart J 2014; 35:1873-80
5. Majeed A, Meijer K, Larrazabal R, Arnberg F, Luijckx GJ, Roberts RS, Schulman S: Mortality in vitamin K antagonistrelated intracerebral bleeding treated with plasma or 4-factor prothrombin complex concentrate. Thromb Haemost 2014; 111:233-9
6. Held C, Hylek EM, Alexander JH, Hanna M, Lopes RD, Wojdyla DM, Thomas L, Al-Khalidi H, Alings M, Xavier D, Ansell J, Goto S, Ruzyllo W, Rosenqvist M, Verheugt FW, Zhu J, Granger CB, Wallentin L: Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: Insights from the ARISTOTLE trial. Eur Heart J 2015; 36:1264-72
7. Zahir H, Brown KS, Vandell AG, Desai M, Maa JF, Dishy V, Lomeli B, Feussner A, Feng W, He L, Grosso MA, Lanz HJ, Antman EM: Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate. Circulation 2015; 131:82-90
8. Martin AC, Le Bonniec B, Fischer AM, Marchand-Leroux C, Gaussem P, Samama CM, Godier A: Evaluation of recombinant activated factor VII, prothrombin complex concentrate, fibrinogen concentrate to reverse apixaban in a rabbit model of bleeding and thrombosis. Int J Cardiol 2013; 168:4228-33
9. Marlu R, Hodaj E, Paris A, Albaladejo P, Cracowski JL, Crackowski JL, Pernod G: Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: A randomised crossover ex vivo study in healthy volunteers. Thromb Haemost 2012; 108:217-24
10. Lee FM, Chan AK, Lau KK, Chan HH: Reversal of new, factorspecific oral anticoagulants by rFVIIa, prothrombin complex concentrate and activated prothrombin complex concentrate: A review of animal and human studies. Thromb Res 2014; 133:705-13
11. Pernod G, Albaladejo P, Godier A, Samama CM, Susen S, Gruel Y, Blais N, Fontana P, Cohen A, Llau JV, Rosencher N, Schved JF, de Maistre E, Samama MM, Mismetti P, Sié P; Working Group on Perioperative Haemostasis: Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: Proposals of the working group on perioperative haemostasis (GIHP)-March 2013. Arch Cardiovasc Dis 2013; 106:382-93
12. Heidbuchel H, Verhamme P, Alings M, Antz M, Diener HC, Hacke W, Oldgren J, Sinnaeve P, Camm AJ, Kirchhof P: Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 2015; 17:1467-507
13. Pollack CV Jr, Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, Dubiel R, Huisman MV, Hylek EM, Kamphuisen PW, Kreuzer J, Levy JH, Sellke FW, Stangier J, Steiner T, Wang B, Kam CW, Weitz JI: Idarucizumab for dabigatran reversal. N Engl J Med 2015; 373:511-20
14. Connolly SJ, Milling TJ Jr, Eikelboom JW, Gibson CM, Curnutte JT, Gold A, Bronson MD, Lu G, Conley PB, Verhamme P, Schmidt J, Middeldorp S, Cohen AT, Beyer-Westendorf J, Albaladejo P, Lopez-Sendon J, Goodman S, Leeds J, Wiens BL, Siegal DM, Zotova E, Meeks B, Nakamya J, Lim WT, Crowther M; ANNEXA-4 Investigators: Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med 2016; 375:1131-41
15. Ghadimi K, Levy JH, Welsby IJ: Prothrombin complex concentrates for bleeding in the perioperative setting. Anesth Analg 2016; 122:1287-300
16. Dickneite G, Hoffman M: Reversing the new oral anticoagulants with prothrombin complex concentrates (PCCs): What is the evidence Thromb Haemost 2014; 111:189-98
17. Schulman S and Kearon C: Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005;3:692-4
18. Kaatz S, Ahmad D, Spyropoulos AC, Schulman S; Subcommittee on Control of Anticoagulation: Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: Communication from the SSC of the ISTH. J Thromb Haemost 2015; 13:2119-26
19. Schulman S, Carrier M, Lee AY, Shivakumar S, Blostein M, Spencer FA, Solymoss S, Barty R, Wang G, Heddle N, Douketis JD; Periop Dabigatran Study Group: Perioperative management of dabigatran: A prospective cohort study. Circulation 2015; 132:167-73
20. Hylek EM, Held C, Alexander JH, Lopes RD, De Caterina R, Wojdyla DM, Huber K, Jansky P, Steg PG, Hanna M, Thomas L, Wallentin L, Granger CB: Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, characteristics, clinical outcomes. J Am Coll Cardiol 2014; 63:2141-7
21. Hankey GJ, Stevens SR, Piccini JP, Lokhnygina Y, Mahaffey KW, Halperin JL, Patel MR, Breithardt G, Singer DE, Becker RC, Berkowitz SD, Paolini JF, Nessel CC, Hacke W, Fox KA, Califf RM; ROCKET AF Steering Committee and Investigators: Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: The rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation. Stroke 2014; 45:1304-12
22. Hart RG, Diener HC, Yang S, Connolly SJ, Wallentin L, Reilly PA, Ezekowitz MD, Yusuf S: Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: The RE-LY trial. Stroke 2012; 43:1511-7
23. Majeed A, Hwang HG, Connolly SJ, Eikelboom JW, Ezekowitz MD, Wallentin L, Brueckmann M, Fraessdorf M, Yusuf S, Schulman S: Management and outcomes of major bleeding during treatment with dabigatran or warfarin. Circulation 2013; 128:2325-32
24. Greinacher A, Thiele T, Selleng K: Reversal of anticoagulants: An overview of current developments. Thromb Haemost 2015; 113:931-42
25. Siegal DM, Curnutte JT, Connolly SJ, Lu G, Conley PB, Wiens BL, Mathur VS, Castillo J, Bronson MD, Leeds JM, Mar FA, Gold A, Crowther MA: Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med 2015; 373:2413-24
26. Ansell JE, Bakhru SH, Laulicht BE, Steiner SS, Grosso M, Brown K, Dishy V, Noveck RJ, Costin JC: Use of PER977 to reverse the anticoagulant effect of edoxaban. N Engl J Med 2014; 371:2141-2
27. Beyer-Westendorf J, Förster K, Pannach S, Ebertz F, Gelbricht V, Thieme C, Michalski F, Köhler C, Werth S, Sahin K, Tittl L, Hänsel U, Weiss N: Rates, management, outcome of rivaroxaban bleeding in daily care: Results from the Dresden NOAC registry. Blood 2014; 124:955-62
28. Honickel M, Treutler S, van Ryn J, Tillmann S, Rossaint R, Grottke O: Reversal of dabigatran anticoagulation ex vivo: Porcine study comparing prothrombin complex concentrates and idarucizumab. Thromb Haemost 2015; 113:728-40
29. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M: Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: A randomized, placebocontrolled, crossover study in healthy subjects. Circulation 2011; 124:1573-9
30. Levi M, Moore KT, Castillejos CF, Kubitza D, Berkowitz SD, Goldhaber SZ, Raghoebar M, Patel MR, Weitz JI, Levy JH: Comparison of three-factor and four-factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers. J Thromb Haemost 2014; 12:1428-36
31. Reilly PA, Lehr T, Haertter S, Connolly SJ, Yusuf S, Eikelboom JW, Ezekowitz MD, Nehmiz G, Wang S, Wallentin L; RE-LY Investigators: The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: The RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol 2014; 63:321-8
32. Samama MM, Contant G, Spiro TE, Perzborn E, Guinet C, Gourmelin Y, Le Flem L, Rohde G, Martinoli JL; Rivaroxaban Anti-Factor Xa Chromogenic Assay Field Trial Laboratories: Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls. Thromb Haemost 2012; 107:379-87
33. Warkentin TE, Margetts P, Connolly SJ, Lamy A, Ricci C, Eikelboom JW: Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding. Blood 2012; 119:2172-4
34. Cuker A, Siegal DM, Crowther MA, Garcia DA: Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants. J Am Coll Cardiol 2014; 64:1128-39
35. Kuramatsu JB, Gerner ST, Schellinger PD, Glahn J, Endres M, Sobesky J, Flechsenhar J, Neugebauer H, Jüttler E, Grau A, Palm F, Röther J, Michels P, Hamann GF, Hüwel J, Hagemann G, Barber B, Terborg C, Trostdorf F, Bäzner H, Roth A, Wöhrle J, Keller M, Schwarz M, Reimann G, Volkmann J, Müllges W, Kraft P, Classen J, Hobohm C, Horn M, Milewski A, Reichmann H, Schneider H, Schimmel E, Fink GR, Dohmen C, Stetefeld H, Witte O, Günther A, Neumann-Haefelin T, Racs AE, Nueckel M, Erbguth F, Kloska SP, Dörfler A, Köhrmann M, Schwab S, Huttner HB: Anticoagulant reversal, blood pressure levels, anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage. JAMA 2015; 313:824-36